ERYTECH Pharma S.A.
Develops red blood cell-based therapies for cancer and orphan diseases.
ERYP | PA
Overview
Corporate Details
- ISIN(s):
- FR0010417360 (+2 more)
- LEI:
- 969500U8ZZCODU8A9374
- Country:
- France
- Address:
- 60 AVENUE ROCKEFELLER, 69008 LYON
- Website:
- https://phaxiam.com/
- Sector:
- Manufacturing
Description
ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on its proprietary ERYCAPS platform, which encapsulates drug substances inside red blood cells. This technology is designed to improve the efficacy and safety of treatments by prolonging the drug's circulation time and reducing side effects. The company's primary focus is on developing treatments for severe forms of cancer and orphan diseases. Its lead product candidate, eryaspase, encapsulates the enzyme L-asparaginase to starve cancer cells of essential nutrients, targeting indications such as acute lymphoblastic leukemia and pancreatic cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-12-14 07:30 |
ERYTECH annonce la levée de 7,85 millions de dollars dans le cadre d’une Regist…
|
French | 311.6 KB | ||
| 2021-12-14 07:30 |
ERYTECH Announces $7.85 Million Registered Direct Offering
|
English | 289.4 KB | ||
| 2021-12-13 22:05 |
ERYTECH annonce la présentation des résultats du programme d’accès élargi dans …
|
French | 374.9 KB | ||
| 2021-12-13 22:05 |
ERYTECH Announces Presentation of Results of Expanded Access Program in ALL at …
|
English | 366.7 KB | ||
| 2021-12-10 18:00 |
Monthly information related to total number of voting rights and shares composi…
|
English | 122.2 KB | ||
| 2021-12-10 18:00 |
Information mensuelle relative au nombre total de droits de vote et d’actions c…
|
French | 213.1 KB | ||
| 2021-11-29 22:05 |
ERYTECH Secures US Patent Directed to Sequential Use of Methioninase & Asparagi…
|
English | 269.9 KB | ||
| 2021-11-29 22:05 |
ERYTECH obtient un brevet aux Etats-Unis pour l’utilisation de la méthioninase …
|
French | 258.1 KB | ||
| 2021-11-15 22:05 |
ERYTECH Provides Business and Financial Update for the Third Quarter of 2021
|
English | 367.8 KB | ||
| 2021-11-15 22:05 |
ERYTECH fait le point sur ses activités et publie ses résultats du troisième tr…
|
French | 305.0 KB | ||
| 2021-11-15 07:30 |
ERYTECH annonce la présentation d’un poster lors du congrès annuel 2021 de l'Am…
|
French | 277.6 KB | ||
| 2021-11-15 07:30 |
ERYTECH Announces Upcoming Poster Presentation at the 2021 American Society of …
|
English | 251.6 KB | ||
| 2021-11-10 07:30 |
ERYTECH annonce la publication d'un article sur la caractérisation des globule…
|
French | 270.5 KB | ||
| 2021-11-10 07:30 |
ERYTECH Announces Publication of a Paper on Red-Blood Cell Characterization in …
|
English | 272.4 KB | ||
| 2021-11-09 08:00 |
ERYTECH to Present at the 12th Annual Jefferies Global London Healthcare Confer…
|
English | 294.4 KB |
Automate Your Workflow. Get a real-time feed of all ERYTECH Pharma S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ERYTECH Pharma S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ERYTECH Pharma S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-06-23 | N/A | Other | Other | 3,697,533 | 2,255,495.13 EUR |
| 2023-06-23 | N/A | Other | Other | 71,839 | 43,821.79 EUR |
| 2023-06-23 | N/A | Other | Other | 54,862 | 33,465.82 EUR |
Peer Companies
